Skip to main content

Table 2 Recurrence pattern

From: Adjuvant therapy with gemcitabine and stereotactic body radiation therapy versus gemcitabine alone for resected stage II pancreatic cancer: a prospective, randomized, open-label, single center trial

 

Whole Cohort (n = 38)

GEM Arm

(n = 20)

GEM + SBRT Arm (n = 18)

P

Number of patients with recurrence, n (%)

34 (89.5%)

18 (90.0%)

16 (88.9%)

0.911

All recurrence events, n

42

22

20

-

Locoregional recurrence, n (%)

15 (35.7%)

9 (40.9%)

6 (30.0%)

0.463

Systemic recurrence, n (%)

Liver

15 (35.7%)

6 (27.3%)

9 (45.0%)

0.208

Lung

4 (9.5%)

3 (13.6%)

1 (5.0%)

0.344

Peri-aortic lymph node

3 (7.1%)

1 (4.6%)

2 (10.0%)

0.485

Peritoneum

5 (11.9%)

3 (13.6%)

2 (10.0%)

0.723